Improving Service for Young Adults

A young man takes hiss experience with lymphoma and uses it to help others:

"Kids were the furthest thought from Matt Lowney's mind when he was diagnosed with non-Hodgkin's lymphoma at 24.

A recent graduate of Oregon State University, Lowney had settled into a new job in 2004 when doctors put him on aggressive chemotherapy. No one mentioned fertility concerns.

"When I was going through it, they didn't bring up the fact that you probably want to go to a fertility clinic and bank up some sperm," Lowney says.

A year later his cancer came back and Lowney transferred to a medical team at OHSU Hospital for chemotherapy, radiation and for a bone marrow transplant. Doctors warned him he was likely infertile.

"It never even occurred to me," says Lowney, to question the side effects of chemo. "And it wasn't in the literature that we were given."

Lowney, in remission now, has become an advocate for young adult cancer patients, typically between 15 and 40 and facing an entirely different set of concerns than children or older adults with cancer. "

Read More: http://www.oregonlive.com/health/index.ssf/2010/11/adovcates_for_young_a...

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap